<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; American Oriental Bioengineering Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/american-oriental-bioengineering-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AOB) American Oriental Bioengineering &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/05/28/aob-american-oriental-bioengineering-bear-of-the-day-2/38820</link>
		<comments>http://www.stockbloghub.com/2010/05/28/aob-american-oriental-bioengineering-bear-of-the-day-2/38820#comments</comments>
		<pubDate>Fri, 28 May 2010 14:19:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Oriental Bioengineering Inc]]></category>
		<category><![CDATA[AOB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38820</guid>
		<description><![CDATA[American Oriental Bioengineering&#8217;s (AOB) first quarter earnings per share came in at $0.04, well below both the Zacks Consensus Estimate of $0.07 and $0.10 reported in the year-ago period. Although revenues recorded a 16.7% year-over-year increase to $53.7 million, we remain concerned about the declining operating margin. Prescription drug sales should continue their growth trajectory as China aims to reform its health care sector to incorporate unaddressed rural markets. However, in the highly fragmented Chinese pharmaceutical industry, AOB&#8217;s expenses are likely to increase given the need to stay ahead of its competitors and to meet stringent manufacturing norms. We maintain our Underperform recommendation on the stock. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/28/aob-american-oriental-bioengineering-bear-of-the-day-2/38820/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AOB) American Oriental Bioengineering &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/05/18/aob-american-oriental-bioengineering-bear-of-the-day/37508</link>
		<comments>http://www.stockbloghub.com/2010/05/18/aob-american-oriental-bioengineering-bear-of-the-day/37508#comments</comments>
		<pubDate>Tue, 18 May 2010 15:48:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Oriental Bioengineering Inc]]></category>
		<category><![CDATA[AOB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37508</guid>
		<description><![CDATA[American Oriental Bioengineering&#8217;s (AOB) first quarter earnings per share came in at $0.04, well below both the Zacks Consensus Estimate of $0.07 and $0.10 reported in the year-ago period. Although revenues recorded a 16.7% year-over-year increase to $53.7 million, we remain concerned about the declining operating margin. Prescription drug sales should continue their growth trajectory as China aims to reform its health care sector to incorporate unaddressed rural markets. However, in the highly fragmented Chinese pharmaceutical industry, AOB&#8217;s expenses are likely to increase given the need to stay ahead of its competitors and to meet stringent manufacturing norms. We maintain our Underperform recommendation on the stock with a price target of $3. Our target price is based on 6.5X our 2010 EPS estimate of $0.46. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/18/aob-american-oriental-bioengineering-bear-of-the-day/37508/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AOB) American Oriental Bioengineering Marginally Beats Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2010/03/18/aob-american-oriental-bioengineering-marginally-beats-earnings-expectations/30879</link>
		<comments>http://www.stockbloghub.com/2010/03/18/aob-american-oriental-bioengineering-marginally-beats-earnings-expectations/30879#comments</comments>
		<pubDate>Thu, 18 Mar 2010 19:12:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Oriental Bioengineering Inc]]></category>
		<category><![CDATA[AOB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30879</guid>
		<description><![CDATA[American Oriental Bioengineering’s (AOB) fourth-quarter earnings per share (EPS) came in at 14 cents surpassing the Zacks Consensus Estimate of 12 cents and 10 cents reported in the year-ago period. For 2009, the company reported EPS of 53 cents, compared to last year’s 61 cents. The company derives revenue from two operating segments–Manufacturing and Distribution. During the quarter, Manufacturing accounted for more than 95% of the company’s total revenue. The company generated $3.6 million from its Distribution business, Nuo Hua, during the reported quarter. For the full year and the fourth quarter of 2009, American Oriental generated total revenue of $296 million (up 12%) and $100 million (up 3.9% year over year), respectively. American Oriental records Manufacturing revenues from two sources – Pharmaceutical and Nutraceutical products. Both recorded an increase ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/aob-american-oriental-bioengineering-marginally-beats-earnings-expectations/30879/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AOB) American Oriental Bioengineering&#8217;s Earnings Disappoint</title>
		<link>http://www.stockbloghub.com/2009/11/18/aob-american-oriental-bioengineerings-earnings-disappoint/20872</link>
		<comments>http://www.stockbloghub.com/2009/11/18/aob-american-oriental-bioengineerings-earnings-disappoint/20872#comments</comments>
		<pubDate>Wed, 18 Nov 2009 22:50:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Oriental Bioengineering Inc]]></category>
		<category><![CDATA[AOB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20872</guid>
		<description><![CDATA[American Oriental Bioengineering’s (AOB) third quarter earnings per share came in at 13 cents, well below the Zacks Consensus Estimate of 19 cents and 21 cents in the year ago period. The company derives revenues from two operating segments – Manufacturing and Distribution. During the quarter, Manufacturing accounted for more than 95% of the company’s total revenues. Total revenues increased 11.7% year over year to $78.8 million. American Oriental records Manufacturing revenues from two sources – Pharmaceutical and Nutraceutical products. Both sources recorded an increase of 6.3% to $66 million and 8.2% to $9.2 million, respectively, compared to the third quarter of 2008. The company generated $3.6 million from its Distribution business during the reported quarter. Revenues from prescription pharmaceutical products increased 22.7% to $29.8 million during the quarter, primarily ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/18/aob-american-oriental-bioengineerings-earnings-disappoint/20872/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

